Thyroid News

The field of endocrinology saw many advancements in 2024 and more developments and innovations are anticipated in 2025.

In a review of the 2024 milestones, Healio | Endocrine Today compiled a list of drugs and devices related to the field that were newly approved, cleared or had label or indication changes. Information was gathered from the FDA website and news releases. We put our best effort into making a complete list and regret any omission. Appearance of a drug or device does not constitute any endorsement by Healio | Endocrine Today, its editors, publishers or editorial board. — The Editors

KOLOA, Hawaii — Effective management of thyroid eye disease requires a focus on mitigating modifiable risk factors, according to a presenter at Hawaiian Eye 2025.

Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release from Sling Therapeutics.

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a DPP-IV inhibitor, according to findings published in Thyroid.

According to results published in the Journal of Shoulder and Elbow Surgery, patients with hypothyroidism may be at an increased risk for medical and implant-related complications after total shoulder arthroplasty vs. controls.

Adults with low-risk thyroid cancer who underwent surgery had significant reductions in cancer-related fear and worry after their procedure compared with before surgery, researchers reported.

Suicide rates for individuals diagnosed with cancer increased over the past 2 decades, according to results of a retrospective study.

Patients with primary thyroid cancer who received radioactive iodine exhibited increased risk for melanoma and other nonkeratinocyte skin cancers, according to study results.